title: Cardiovascular Complications of HIV Infection.
abstract: HIV-infected individuals are at increased risk for cardiovascular events. Widely used cardiovascular disease (CVD) risk calculators to determine indications for statin treatment are not well validated for use in the HIV-infecte population. Some experts advocate including HIV infection as an independent risk factor for CVD. The effects of antiretroviral therapy on lipid profiles and the potentially increased risk for cardiovascular events must be taken into account when selecting treatment for HIV-infected individuals. There is increasing evidence that chronic immune activation and inflammation play a role in the pathogenesis of CVD in the context of HIV infection. This article summarizes a presentation by Marshall J. Glesby, MD, PhD, at the Ryan White HIV/AIDS Program Clinical Care Conference held in New Orleans, Louisiana, in December 2015.
authors.affiliation: Weill Cornell Medicine, New York, NY, USA.
authors.forename: Marshall J
authors.initials: MJ
authors.lastname: Glesby
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000453:epidemiology* / Q000473:pathology*; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans
chemical_list: D019380:Anti-HIV Agents